European Journal of Medicinal Chemistry

Article	Citations
Oxidative stress mitigation by antioxidants - An overview on their chemistry and influences on health status	393
Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review	302
β-lactam antibiotics: An overview from a medicinal chemistry perspective	287
Alzheimer’s disease and its treatment by different approaches: A review	246
An insight on medicinal attributes of 1,2,4-triazoles	192
Bioactive pyrrole-based compounds with target selectivity	152
A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer’s disease agents: A review	151
Application of sulfoximines in medicinal chemistry from 2013 to 2020	149
RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic	149
Antibacterial activities with the structure-activity relationship of coumarin derivatives	137
Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges	132
Research progress of mTOR inhibitors	130
Small molecule selenium-containing compounds: Recent development and therapeutic applications	130
The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020	123
Toll-like receptor 4 (TLR4) inhibitors: Current research and prospective	112
Synthetic and medicinal perspective of quinolines as antiviral agents	109
Pyrazole-based analogs as potential antibacterial agents against methicillin-resistance staphylococcus aureus (MRSA) and its SAR elucidation	108
Sulfonamide derivatives as potential anti-cancer agents and their SARs elucidation	106
Treatment for liver cancer: From sorafenib to natural products	104
Plant isoquinoline alkaloids: Advances in the chemistry and biology of berberine	104
Quercetin derivatives: Drug design, development, and biological activities, a review	100
Therapeutic strategies to overcome cisplatin resistance in ovarian cancer	93
Recent advances in the medicinal chemistry of carbonic anhydrase inhibitors	91
Drug repositioning: Progress and challenges in drug discovery for various diseases	90
Cancer multidrug-resistance reversal by ABCB1 inhibition: A recent update	89

Recent advancements in the development of bioactive pyrazoline derivatives	87
A review: Biologically active 3,4-heterocycle-fused coumarins	86
Current development of CBP/p300 inhibitors in the last decade	84
FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application	83
Discovery of natural anti-inflammatory alkaloids: Potential leads for the drug discovery for the treatment of inflammation	82
Camptothecin's journey from discovery to WHO Essential Medicine: Fifty years of promise	82
A review: Pharmacological aspects of metal based 1,2,4-triazole derived Schiff bases	82
A review on the structure and pharmacological activity of phenylethanoid glycosides	81
Antimicrobial drugs bearing guanidine moieties: A review	81
The application of isatin-based multicomponent-reactions in the quest for new bioactive and druglike molecules	80
PROTACs to address the challenges facing small molecule inhibitors	79
Chemotherapy and chemo-resistance in nasopharyngeal carcinoma	79
1,2,3-Triazole-containing hybrids with potential antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA)	78
Synthetic α-glucosidase inhibitors as promising anti-diabetic agents: Recent developments and future challenges	78
Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment	77
Developments of CRBN-based PROTACs as potential therapeutic agents	76
Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies	75
Recent accomplishments on the synthetic/biological facets of pharmacologically active 1H-1,2,3-triazoles	75
Azithromycin: The First Broad-spectrum Therapeutic	74
Recent advances in the design and discovery of synthetic tyrosinase inhibitors	71
Research progress of indole compounds with potential antidiabetic activity	71
Exosomes from different cells: Characteristics, modifications, and therapeutic applications	70
Chemistry, biosynthesis and biological activity of terpenoids and meroterpenoids in bacteria and fungi isolated from different marine habitats	69
The nano delivery systems and applications of mRNA	68
Anticancer potential of spirocompounds in medicinal chemistry: A pentennial expedition	67
β-Carbolines as potential anticancer agents	67
Molecular hybrids: A five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy	67
Pt(II) and Au(III) complexes containing Schiff-base ligands: A promising source for antitumor treatment	67
Potentials of nanotechnology in treatment of methicillin-resistant Staphylococcus aureus	67
Structural insights of oxindole based kinase inhibitors as anticancer agents: Recent advances	67
First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo	67
A review on ferulic acid and analogs based scaffolds for the management of Alzheimer’s disease	66
A key review on oxadiazole analogs as potential methicillin-resistant Staphylococcus aureus (MRSA) activity: Structure-activity relationship studies	66
Chalcones: Unearthing their therapeutic possibility as monoamine oxidase B inhibitors	66
Recent advances in DDR (DNA damage response) inhibitors for cancer therapy	66
Therapeutic progression of quinazolines as targeted chemotherapeutic agents	65
Pyridazine as a privileged structure: An updated review on anticancer activity of pyridazine containing bioactive molecules	64
Discovery of potent small molecule PROTACs targeting mutant EGFR	64
Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systems	63
Improved SARS-CoV-2 Mpro inhibitors based on feline antiviral drug GC376: Structural enhancements, increased solubility, and micellar studies	63
Discovery of unique thiazolidinone-conjugated coumarins as novel broad spectrum antibacterial agents	63
Coumarin–benzimidazole hybrids: A review of developments in medicinal chemistry	63
Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF3) derivatives as potential anticancer agents	62
Alzheimer's disease: Updated multi-targets therapeutics are in clinical and in progress	62
Pyrimidine-based EGFR TK inhibitors in targeted cancer therapy	62
The role of imidazole and benzimidazole heterocycles in Chagas disease: A review	62
Membrane active 7-thiazoxime quinolones as novel DNA binding agents to decrease the genes expression and exert potent anti-methicillin-resistant Staphylococcus aureus activity	61
The state of the art of PROTAC technologies for drug discovery	61
Current status and future prospects of p38α/MAPK14 kinase and its inhibitors	61
Xanthenes in Medicinal Chemistry – Synthetic strategies and biological activities	60

DYRK1A inhibitors for disease therapy: Current status and perspectives	60
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors	59
Hydroxamate siderophores: Natural occurrence, chemical synthesis, iron binding affinity and use as Trojan horses against pathogens	59
Recent advances of quinones as a privileged structure in drug discovery	59
Inhibitors of gelatinases (MMP-2 and MMP-9) for the management of hematological malignancies	58
Targeting estrogen receptor α for degradation with PROTACs: A promising approach to overcome endocrine resistance	57
A comprehensive review on β-lapachone: Mechanisms, structural modifications, and therapeutic potentials	57
Application and synthesis of thiazole ring in clinically approved drugs	56
Andrographolide and its derivatives: Current achievements and future perspectives	55
Development of Mcl-1 inhibitors for cancer therapy	55
Recent applications of vinyl sulfone motif in drug design and discovery	54
Vitamin D and its analogs as anticancer and anti-inflammatory agents	54
Novel 2-indolinone thiazole hybrids as sunitinib analogues: Design, synthesis, and potent VEGFR-2 inhibition with potential anti-renal cancer activity	54
Antimalarial application of quinones: A recent update	54
Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC)	53
The heat shock response and small molecule regulators	53
Indomethacin-based PROTACs as pan-coronavirus antiviral agents	53
Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities	53
Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China	53
Small molecule therapeutics for tauopathy in Alzheimer’s disease: Walking on the path of most resistance	53
Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion	53
An insight in anti-malarial potential of indole scaffold: A review	53
5-Fluorouracil nano-delivery systems as a cutting-edge for cancer therapy	52
Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease	52
Recent research progress of Uncaria spp. based on alkaloids: phytochemistry, pharmacology and structural chemistry	52
Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders	52
Synergistic effects of curcumin and its analogs with other bioactive compounds: A comprehensive review	52
Quinoline anticancer agents active on DNA and DNA-interacting proteins: From classical to emerging therapeutic targets	52
Novel coumarin aminophosphonates as potential multitargeting antibacterial agents against Staphylococcus aureus	52
Anticancer boron-containing prodrugs responsive to oxidative stress from the tumor microenvironment	52
Anti-tuberculosis activity and its structure-activity relationship (SAR) studies of oxadiazole derivatives: A key review	52
Discovery of metal-based complexes as promising antimicrobial agents	51
Antimicrobial peptides: Structure, mechanism, and modification	51
Design and characterization of cereblon-mediated androgen receptor proteolysis-targeting chimeras	51
Design, synthesis and in vivo evaluation of 3-arylcoumarin derivatives of rhenium(I) tricarbonyl complexes as potent antibacterial agents against methicillin-resistant Staphylococcus aureus (MRSA)	51
3-Methylthiazolo[3,2-a]benzimidazole-benzenesulfonamide conjugates as novel carbonic anhydrase inhibitors endowed with anticancer activity: Design, synthesis, biological and molecular modeling studies	50
Potent inhibitors of SARS-CoV-2 3C-like protease derived from N-substituted isatin compounds	50
Antioxidant, anti-inflammatory and immunomodulatory roles of vitamins in COVID-19 therapy	50
Roles and drug development of METTL3 (methyltransferase-like 3) in anti-tumor therapy	49
Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CLpro covalent inhibitors	49
Efficient targeted oncogenic KRASG12C degradation via first reversible-covalent PROTAC	48
2-Aminothiazole: A privileged scaffold for the discovery of anti-cancer agents	48
Meroterpenoids produced by fungi: Occurrence, structural diversity, biological activities, and their molecular targets	48
The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation	48
Adamantane derivatives as potential inhibitors of p37 major envelope protein and poxvirus reproduction. Design, synthesis and antiviral activity	48
Pluronic-based nanovehicles: Recent advances in anticancer therapeutic applications	47
Overview of all-trans-retinoic acid (ATRA) and its analogues: Structures, activities, and mechanisms in acute promyelocytic leukaemia	47
Design, synthesis, and in vitro and in vivo anti-angiogenesis study of a novel vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor based on 1,2,3-triazole scaffold	47
The antibacterial activity of fluoroquinolone derivatives: An update (2018–2021)	46
Small-molecule MDM2 inhibitors in clinical trials for cancer therapy	46
Recent advances of podophyllotoxin/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: An update (2010–2020)	46
The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022	46
1,2,4-Oxadiazole topsentin analogs as staphylococcal biofilm inhibitors targeting the bacterial transpeptidase sortase A	46
Development of novel benzofuran-based SLC-0111 analogs as selective cancer-associated carbonic anhydrase isoform IX inhibitors	46
A bibliometric analysis of PROTAC from 2001 to 2021	45
2-substituted benzothiazoles as antiproliferative agents: Novel insights on structure-activity relationships	45
Modulators of CFTR. Updates on clinical development and future directions	45
A comprehensive overview of β-carbolines and its derivatives as anticancer agents	45
Emerging small-molecule inhibitors of the Bruton’s tyrosine kinase (BTK): Current development	45
Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib	44
New drug approvals for 2019: Synthesis and clinical applications	44
Medicinal chemistry updates of novel HDACs inhibitors (2020 to present)	44
Dual-target compounds for Alzheimer's disease: Natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR)	44
Targeting EZH2 for cancer therapy: From current progress to novel strategies	44
Small-molecule inhibitors of breast cancer-related targets: Potential therapeutic agents for breast cancer	43
Discovery of novel purinylthiazolylethanone derivatives as anti-Candida albicans agents through possible multifaceted mechanisms	43
Metal-organic frameworks (MOFs) as biomolecules drug delivery systems for anticancer purposes	43
Novel 3-substituted coumarins as selective human carbonic anhydrase IX and XII inhibitors: Synthesis, biological and molecular dynamics analysis	43
Cyclic tailor-made amino acids in the design of modern pharmaceuticals	43
Design and synthesis of 3-(4-pyridyl)-5-(4-sulfamido-phenyl)-1,2,4-oxadiazole derivatives as novel GSK-3β inhibitors and evaluation of their potential as multifunctional anti-Alzheimer agents	42
Structure-activity relationship studies of phenothiazine derivatives as a new class of ferroptosis inhibitors together with the therapeutic effect in an ischemic stroke model	42
Discovery of highly potent tubulin polymerization inhibitors: Design, synthesis, and structure-activity relationships of novel 2,7-diaryl-[1,2,4]triazolo[1,5-a]pyrimidines	42
An unanticipated discovery towards novel naphthalimide corbelled aminothiazoximes as potential anti-MRSA agents and allosteric modulators for PBP2a	42
Natural products from mangrove sediments-derived microbes: Structural diversity, bioactivities, biosynthesis, and total synthesis	42
Tryptophan derived natural marine alkaloids and synthetic derivatives as promising antimicrobial agents	42
Emerging impact of triazoles as anti-tubercular agent	42
Poly ethylene glycol (PEG)-Related controllable and sustainable antidiabetic drug delivery systems	42
A review of synthetic bioactive tetrahydro-β-carbolines: A medicinal chemistry perspective	42
Design, synthesis and evaluation of novel thienopyrimidine-based agents bearing diaryl urea functionality as potential inhibitors of angiogenesis	41
CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment	41

Antibacterial quaternary ammonium agents: Chemical diversity and biological mechanism	41
Design, synthesis and evaluation of new quinazolin-4-one derivatives as apoptotic enhancers and autophagy inhibitors with potent antitumor activity	41
An overview on Estrogen receptors signaling and its ligands in breast cancer	41
Polypharmacological drug actions of recently FDA approved antibiotics	41
An appraisal of anti-mycobacterial activity with structure-activity relationship of piperazine and its analogues: A review	41
Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries	41
Discovery of novel cell-penetrating and tumor-targeting peptide-drug conjugate (PDC) for programmable delivery of paclitaxel and cancer treatment	40
An optimized analog of antimicrobial peptide Jelleine-1 shows enhanced antimicrobial activity against multidrug resistant P. aeruginosa and negligible toxicity in vitro and in vivo	40
STING, a promising target for small molecular immune modulator: A review	40
Synthesis of 1,3,4-oxadiazole derivatives with anticonvulsant activity and their binding to the GABAA receptor	40
Discovery of new phenyl sulfonyl-pyrimidine carboxylate derivatives as the potential multi-target drugs with effective anti-Alzheimer’s action: Design, synthesis, crystal structure and in-vitro biolog	40
Square planar Au(III), Pt(II) and Cu(II) complexes with quinoline-substituted 2,2′:6′,2″-terpyridine ligands: From in vitro to in vivo biological properties	40
Hydrogen sulfide donors: Therapeutic potential in anti-atherosclerosis	40
Antitubercular properties of thiazolidin-4-ones – A review	40
Topoisomerase I inhibitors: Challenges, progress and the road ahead	39
Recent contributions of quinolines to antimalarial and anticancer drug discovery research	39
Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus	39
Therapeutic potential of uracil and its derivatives in countering pathogenic and physiological disorders	39
Biguanides: Species with versatile therapeutic applications	39
Recent advance on carbamate-based cholinesterase inhibitors as potential multifunctional agents against Alzheimer's disease	39
Targeting ferroptosis: Paving new roads for drug design and discovery	39
Factor XII/XIIa inhibitors: Their discovery, development, and potential indications	39
Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy	39
Recent achievements of bioluminescence imaging based on firefly luciferin-luciferase system	39
Dihydropyrimidinone imidazoles as unique structural antibacterial agents for drug-resistant gram-negative pathogens	39
Design, synthesis, and biological evaluation of nitroisoxazole-containing spiro[pyrrolidin-oxindole] derivatives as novel glutathione peroxidase 4/mouse double minute 2 dual inhibitors that inhibit br	39
Non-invasive intranasal administration route directly to the brain using dendrimer nanoplatforms: An opportunity to develop new CNS drugs	39
Recent advances in the design and development of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving agents with diverse therapeutic potential	39
Seeking heterocyclic scaffolds as antivirals against dengue virus	38
Natural products and analogs as preventive agents for metabolic syndrome via peroxisome proliferator-activated receptors: An overview	38
Current status of carbazole hybrids as anticancer agents	38
Aurora kinase inhibitors as potential anticancer agents: Recent advances	38
New organoselenides (NSAIDs-Se derivatives) as potential anticancer agents: Synthesis, biological evaluation and in silico calculations	38
Dual target inhibitors based on EGFR: Promising anticancer agents for the treatment of cancers (2017-)	38
Pharmacological inhibition of ferroptosis as a therapeutic target for sepsis-associated organ damage	38
Novel quinazolinone inhibitors of the Pseudomonas aeruginosa quorum sensing transcriptional regulator PqsR	38
Advance of structural modification of nucleosides scaffold	38
Synthesis of some new benzoxazole derivatives and investigation of their anticancer activities	38
Development of triazolothiadiazine derivatives as highly potent tubulin polymerization inhibitors: Structure-activity relationship, in vitro and in vivo study	38
Design, synthesis and biological evaluation of pyrazole-aromatic containing carboxamides as potent SDH inhibitors	38
Investigating the antibacterial activity of salen/salophene metal complexes: Induction of ferroptosis as part of the mode of action	37
Therapeutic potential of quinazoline derivatives for Alzheimer's disease: A comprehensive review	37
Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010–2020)	37
Anticancer potential of indirubins in medicinal chemistry: Biological activity, structural modification, and structure-activity relationship	37
Recent research and development of NDM-1 inhibitors	37
Adenosine receptor antagonists: Recent advances and therapeutic perspective	37
Pyrimidine derivatives with antitubercular activity	37
Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer	37
Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation	37
Annual review of lysine-specific demethylase 1 (LSD1/KDM1A) inhibitors in 2021	36
Design, synthesis and evaluation of novel bis-substituted aromatic amide dithiocarbamate derivatives as colchicine site tubulin polymerization inhibitors with potent anticancer activities	36
Discovery of a PROTAC targeting ALK with in vivo activity	36
Design and synthesis of quinoline-pyrimidine inspired hybrids as potential plasmodial inhibitors	36
Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes	36
Discovery of novel phenylhydrazone-based oxindole-thiolazoles as potent antibacterial agents toward Pseudomonas aeruginosa	36
Ultra-short lipopeptides against gram-positive bacteria while alleviating antimicrobial resistance	36
Discovery of new carbonic anhydrase IX inhibitors as anticancer agents by toning the hydrophobic and hydrophilic rims of the active site to encounter the dual-tail approach	36
New drug approvals for 2020: Synthesis and clinical applications	36
Synthetically-tailored and nature-derived dual COX-2/5-LOX inhibitors: Structural aspects and SAR	35
Comprehensive study on potent and selective carbonic anhydrase inhibitors: Synthesis, bioactivities and molecular modelling studies of 4-(3-(2-arylidenehydrazine-1-carbonyl)-5-(thiophen-2-yl)-1H-pyraz	35
Optimization of pyrazolo[1,5-a]pyrimidines lead to the identification of a highly selective casein kinase 2 inhibitor	35
Highlights on U.S. FDA-approved fluorinated drugs over the past five years (2018–2022)	35
Overview of piperlongumine analogues and their therapeutic potential	35
Natural products and synthetic analogues against HIV: A perspective to develop new potential anti-HIV drugs	35
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review	35
An update into the medicinal chemistry of translocator protein (TSPO) ligands	35
Recent advances in biological activities of rhodium complexes: Their applications in drug discovery research	35
Recent updates on 1,2,3-triazole-containing hybrids with in vivo therapeutic potential against cancers: A mini-review	34
Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis	34
4-(3H)-quinazolinones N-3 substituted with a five membered heterocycle: A promising scaffold towards bioactive molecules	34
Application of carbohydrates in approved small molecule drugs: A review	34
The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2	34
Design, synthesis, and biological evaluation of carbamate derivatives of N-salicyloyl tryptamine as multifunctional agents for the treatment of Alzheimer's disease	34
Development of targeted nanoparticles loaded with antiviral drugs for SARS-CoV-2 inhibition	34
Advances of CCR5 antagonists: From small molecules to macromolecules	34
Indole scaffolds as a promising class of the aryl hydrocarbon receptor ligands	34
An update of new small-molecule anticancer drugs approved from 2015 to 2020	34
Design, synthesis and biological assessment of new selective COX-2 inhibitors including methyl sulfonyl moiety	34
Tailor-made amino acids in the design of small-molecule blockbuster drugs	34
Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor	34
Novel phthalide derivatives: Synthesis and anti-inflammatory activity in vitro and in vivo	34
Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors	34
Tandem construction of biological relevant aliphatic 5-membered N-heterocycles	34
Engagement of phytoestrogens in breast cancer suppression: Structural classification and mechanistic approach	34
FabI (enoyl acyl carrier protein reductase) - A potential broad spectrum therapeutic target and its inhibitors	34
Progress in developing MNK inhibitors	33
Amyloid-β and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review	33
Squaric acid analogues in medicinal chemistry	33
Novel cannabidiol−carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease	33
Synthesis, DNA binding, antibacterial and anticancer properties of two novel water-soluble copper(II) complexes containing gluconate	33
Chemodynamic therapy agents Cu(II) complexes of quinoline derivatives induced ER stress and mitochondria-mediated apoptosis in SK-OV-3 cells	33
Design, synthesis and biological evaluation of new benzoxazolone/benzothiazolone derivatives as multi-target agents against Alzheimer’s disease	33
Metabolomics-assisted discovery of a new anticancer GLS-1 inhibitor chemotype from a nortopsentin-inspired library: From phenotype screening to target identification	33
Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure–activity relationship and biological activity as potential antitumor and anticonvulsant agents	33
PROTACs: New method to degrade transcription regulating proteins	33